HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RIGL
Rigel Pharmaceuticals, Inc.
RIGL's fundamentals are mixed, but it looks cheap: trading at 2.8x earnings, less than half its usual 6.5x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RIGL Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
RIGL's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RIGL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2x | $31.38 | -31% |
| Current | 2.8x | $45.69 | — |
| Fair | 6.3x | $102 | +122% |
| Forward | 13x | $45.69 | — |
| Expensive | 20x | $329 | +620% |
Historical ranges are pointers, not guarantees.
RIGL's PE is in its cheap range at 2.8x. On analysts' estimates for next year's earnings, today's price would be 13x, in its expensive range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RIGL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for RIGL, but weaker profitability.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RIGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.54 | -78% |
| Q3 2026 | $16.08 | +159% |
| Q2 2026 | $16.89 | +209% |
| Q1 2026 | $19.29 | +810% |
| Q4 2025 | $19.48 | +1868% |
| Q3 2025 | $6.22 | +2492% |
| Q2 2025 | $5.46 | +$6.22 |
| Q1 2025 | $2.12 | +$3.22 |
| Q4 2024 | $0.99 | +$2.39 |
RIGL has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RIGL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RIGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.9M | +16% |
| Q2 2026 | $78.7M | -23% |
| Q1 2026 | $58.8M | +10% |
| Q4 2025 | $69.8M | +21% |
| Q3 2025 | $69.5M | +26% |
| Q2 2025 | $101.7M | +176% |
| Q1 2025 | $53.3M | +81% |
| Q4 2024 | $57.6M | +61% |
RIGL's revenue is recovering but still below its 2025 peak: $81M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -20 points |
| Q2 2026 | 30% | -30 points |
| Q1 2026 | 20% | -3.7 points |
| Q4 2025 | 33% | +4.3 points |
| Q3 2025 | 41% | +16 points |
| Q2 2025 | 60% | +59 points |
| Q1 2025 | 24% | +48 points |
| Q4 2024 | 29% | +23 points |
RIGL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
RIGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.6M | +44% |
| Q2 2026 | $30.7M | +0.4% |
| Q1 2026 | $2.7M | +$3.6M |
| Q4 2025 | $22M | +52% |
| Q3 2025 | $24M | +11% |
| Q2 2025 | $30.5M | +10012% |
| Q1 2025 | -$893K | +$4.1M |
| Q4 2022 | -$22M | -$2.9M |
RIGL generated $90M in free cash flow over the past year, up 32% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RIGL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RIGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.4% | +869K shares |
| 1 year | +6.7% | +1.3M shares |
| 3 years | +17% | +3M shares |
| 5 years | +20% | +3.4M shares |
| Available history | +22% | +3.7M shares |
RIGL has 20M diluted shares, up 6.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1M |
| Q2 2026 | $511,000 |
| Q1 2026 | $3.7M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RIGL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
RIGL has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RIGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 55.3 | Neutral |
RIGL's weekly RSI is 54 (neutral) and its Stochastic is 55 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RIGL PE vs Healthcare Sector
| Metric | RIGL | Sector median | Relative |
|---|---|---|---|
| PE | 2.8x | 26x | 89% below |
| PE % | 30 | 29 | 1 pt above |
RIGL is trading at 2.8x earnings, a 89% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RIGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 2.6% below |
| 20 week MA | $44.4 | 2.9% above |
| 50 week MA | $38.0 | 20% above |
| 100 week MA | $31.6 | 45% above |
| 200 week MA | $22.4 | 104% above |
RIGL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RIGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.8 | $36.9 | +77% |
| 2021 | $36.9 | $28.4 | -23% |
| 2022 | $28.4 | $12.3 | -57% |
| 2023 | $12.3 | $14.5 | +18% |
| 2024 | $14.5 | $16.5 | +14% |
| 2025 | $16.5 | $44.0 | +167% |
| 2026 YTD | $44.0 | $45.7 | +3.8% |
RIGL has the edge over HIMS on returns for 2026, with the stronger performance.